Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
RP Taylor, MA Lindorfer - Blood, The Journal of the American …, 2015 - ashpublications.org
RP Taylor, MA Lindorfer
Blood, The Journal of the American Society of Hematology, 2015•ashpublications.orgA specialized form of trogocytosis occurs when Fcγ receptors on acceptor cells take up and
internalize donor cell-associated immune complexes composed of specific monoclonal
antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an
example of antigenic modulation, has been described in recent clinical correlative studies
and in vitro investigations for several mAbs used in cancer immunotherapy, including
rituximab and ofatumumab. We discuss the impact of Fcγ-receptor–mediated trogocytosis on …
internalize donor cell-associated immune complexes composed of specific monoclonal
antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an
example of antigenic modulation, has been described in recent clinical correlative studies
and in vitro investigations for several mAbs used in cancer immunotherapy, including
rituximab and ofatumumab. We discuss the impact of Fcγ-receptor–mediated trogocytosis on …
Abstract
A specialized form of trogocytosis occurs when Fcγ receptors on acceptor cells take up and internalize donor cell-associated immune complexes composed of specific monoclonal antibodies (mAbs) bound to target antigens on donor cells. This trogocytosis reaction, an example of antigenic modulation, has been described in recent clinical correlative studies and in vitro investigations for several mAbs used in cancer immunotherapy, including rituximab and ofatumumab. We discuss the impact of Fcγ-receptor–mediated trogocytosis on the efficacy of cancer immunotherapy and other mAb-based therapies.
ashpublications.org